Optimeos Life Sciences has developed a novel nanoparticle platform for the intracellular delivery of RNA and DNA therapeutics, enabling the co-encapsulation of multiple active pharmaceutical ingredients while enhancing tissue targeting and reducing immune activation. This technology addresses the limitations of traditional lipid nanoparticle systems, offering a superior dosing profile for more effective disease modification.
Funding
$6.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NFounders
Product
Problem
Current lipid nanoparticle (LNP) delivery systems for RNA and DNA therapeutics have limitations in tissue targeting, payload capacity, and immunogenicity, hindering the effectiveness of next-generation genetic medicines. Traditional LNPs often trigger unwanted immune responses and struggle to co-deliver multiple active pharmaceutical ingredients (APIs) for complex therapeutic strategies.
Solution
Optimeos Life Sciences has developed a novel nanoparticle platform for intracellular delivery of RNA and DNA therapeutics, overcoming the limitations of existing LNP technologies. The platform enables co-encapsulation of multiple APIs, including mRNA, siRNA, DNA, and adjuvants, allowing for combination therapies and enhanced therapeutic effects. Modular particle assembly facilitates targeted delivery to specific tissues, improving drug efficacy and reducing off-target effects. The platform's tunable immunogenicity allows for reduced immune activation in protein replacement therapies or enhanced immune stimulation for vaccine applications.
Target Audience
Optimeos's primary customers are biopharmaceutical companies developing RNA and DNA therapeutics, as well as researchers and institutions focused on advanced drug delivery systems.
Features
- Tunable immunogenicity through nanoparticles that do not require cationic lipids or cationic polymers
- Co-encapsulation of multiple APIs, such as mRNA, siRNA, tRNA, DNA, ASO, proteins, peptides, small molecules, or adjuvants
- Modular particle assembly for enhanced tissue targeting
- Technology enables a higher payload content for more efficient disease modification